Crossmark

Long-term follow-up results of anti-BCMA CAR-T cell therapy combined with autologous hematopoietic stem cell transplantation in relapsed/refractory multiple myeloma with extramedullary disease

Crossref DOI link: https://doi.org/10.1186/s12967-026-08302-y

Published Online: 2026-05-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Xin

Liu, Can

Niu, Siyan

Li, Ru

Gao, Shuquan

Cui, Rui

Wang, Jia

Qi, Yao

Li, Jingyi

Deng, Qi https://orcid.org/0000-0002-3646-4953
Funding

Funding for this research was provided by:

Tianjin Natural Science Foundation Project (25JCZDJC00830)
License Information

Text and Data Mining valid from 2026-05-25

Accepted Manuscript valid from 2026-05-25
More Information

Article History

Received: 12 January 2026

Accepted: 11 May 2026

First Online: 25 May 2026

Declarations

:

: This study was approved by the Medical Ethics Committee of the Department of Hematology, Tianjin First Center Hospital (Tianjin, China). (Approved No. of ethic committee: 2020N028KY). The Clinical trial in our study was registered at as ChiCTR2000033925.

: Not applicable.

: None declared.

Document is current

Any future updates will be listed below